Logo image of CTRN

CITI TRENDS INC (CTRN) Stock Fundamental Analysis

NASDAQ:CTRN - Nasdaq - US17306X1028 - Common Stock - Currency: USD

30.83  +0.09 (+0.29%)

After market: 30.83 0 (0%)

Fundamental Rating

3

Taking everything into account, CTRN scores 3 out of 10 in our fundamental rating. CTRN was compared to 122 industry peers in the Specialty Retail industry. CTRN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CTRN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CTRN has reported negative net income.
CTRN had a positive operating cash flow in the past year.
In multiple years CTRN reported negative net income over the last 5 years.
In multiple years CTRN reported negative operating cash flow during the last 5 years.
CTRN Yearly Net Income VS EBIT VS OCF VS FCFCTRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M

1.2 Ratios

Looking at the Return On Assets, with a value of -8.89%, CTRN is doing worse than 74.59% of the companies in the same industry.
CTRN has a worse Return On Equity (-35.81%) than 65.57% of its industry peers.
Industry RankSector Rank
ROA -8.89%
ROE -35.81%
ROIC N/A
ROA(3y)-0.27%
ROA(5y)3.43%
ROE(3y)-3.45%
ROE(5y)11.58%
ROIC(3y)N/A
ROIC(5y)N/A
CTRN Yearly ROA, ROE, ROICCTRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40

1.3 Margins

CTRN has a Gross Margin of 37.71%. This is comparable to the rest of the industry: CTRN outperforms 54.92% of its industry peers.
In the last couple of years the Gross Margin of CTRN has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for CTRN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 37.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.05%
GM growth 5Y-0.3%
CTRN Yearly Profit, Operating, Gross MarginsCTRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

More info and screens

6

2. Health

2.1 Basic Checks

CTRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
CTRN has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for CTRN has been reduced compared to 5 years ago.
There is no outstanding debt for CTRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CTRN Yearly Shares OutstandingCTRN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
CTRN Yearly Total Debt VS Total AssetsCTRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

CTRN has an Altman-Z score of 2.94. This is not the best score and indicates that CTRN is in the grey zone with still only limited risk for bankruptcy at the moment.
CTRN has a Altman-Z score of 2.94. This is in the better half of the industry: CTRN outperforms 66.39% of its industry peers.
There is no outstanding debt for CTRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.94
ROIC/WACCN/A
WACC9.59%
CTRN Yearly LT Debt VS Equity VS FCFCTRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M

2.3 Liquidity

CTRN has a Current Ratio of 1.12. This is a normal value and indicates that CTRN is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of CTRN (1.12) is worse than 66.39% of its industry peers.
A Quick Ratio of 0.39 indicates that CTRN may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.39, CTRN is doing worse than 60.66% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.12
Quick Ratio 0.39
CTRN Yearly Current Assets VS Current LiabilitesCTRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for CTRN have decreased strongly by -330.53% in the last year.
CTRN shows a small growth in Revenue. In the last year, the Revenue has grown by 1.85%.
CTRN shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.75% yearly.
EPS 1Y (TTM)-330.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%153.13%
Revenue 1Y (TTM)1.85%
Revenue growth 3Y-8.76%
Revenue growth 5Y-0.75%
Sales Q2Q%8.29%

3.2 Future

The Earnings Per Share is expected to grow by 24.22% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 6.03% on average over the next years.
EPS Next Y73.05%
EPS Next 2Y47.36%
EPS Next 3Y35.42%
EPS Next 5Y24.22%
Revenue Next Year4.65%
Revenue Next 2Y4.63%
Revenue Next 3Y4.99%
Revenue Next 5Y6.03%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CTRN Yearly Revenue VS EstimatesCTRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
CTRN Yearly EPS VS EstimatesCTRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4 6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

CTRN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 39.25, which means the current valuation is very expensive for CTRN.
CTRN's Price/Forward Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.44, CTRN is valued at the same level.
Industry RankSector Rank
PE N/A
Fwd PE 39.25
CTRN Price Earnings VS Forward Price EarningsCTRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTRN Per share dataCTRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80

4.3 Compensation for Growth

CTRN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CTRN's earnings are expected to grow with 35.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y47.36%
EPS Next 3Y35.42%

More info and screens

0

5. Dividend

5.1 Amount

CTRN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CITI TRENDS INC

NASDAQ:CTRN (7/18/2025, 8:00:01 PM)

After market: 30.83 0 (0%)

30.83

+0.09 (+0.29%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)06-03 2025-06-03/bmo
Earnings (Next)08-25 2025-08-25/bmo
Inst Owners94.74%
Inst Owner Change0%
Ins Owners10.73%
Ins Owner Change1.02%
Market Cap255.58M
Analysts82.5
Price Target39.27 (27.38%)
Short Float %6.28%
Short Ratio4.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-376.65%
Min EPS beat(2)-938.78%
Max EPS beat(2)185.47%
EPS beat(4)1
Avg EPS beat(4)-258.15%
Min EPS beat(4)-938.78%
Max EPS beat(4)185.47%
EPS beat(8)2
Avg EPS beat(8)-156.03%
EPS beat(12)4
Avg EPS beat(12)-105.71%
EPS beat(16)8
Avg EPS beat(16)-56.54%
Revenue beat(2)1
Avg Revenue beat(2)-0.59%
Min Revenue beat(2)-2.13%
Max Revenue beat(2)0.95%
Revenue beat(4)1
Avg Revenue beat(4)-1.8%
Min Revenue beat(4)-3.37%
Max Revenue beat(4)0.95%
Revenue beat(8)2
Avg Revenue beat(8)-1.87%
Revenue beat(12)3
Avg Revenue beat(12)-2.19%
Revenue beat(16)6
Avg Revenue beat(16)-1.66%
PT rev (1m)26.23%
PT rev (3m)26.23%
EPS NQ rev (1m)-10.33%
EPS NQ rev (3m)-10.33%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.83%
Revenue NQ rev (1m)0.76%
Revenue NQ rev (3m)2.59%
Revenue NY rev (1m)0.84%
Revenue NY rev (3m)0.84%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 39.25
P/S 0.33
P/FCF N/A
P/OCF 53.29
P/B 2.35
P/tB 2.35
EV/EBITDA N/A
EPS(TTM)-4.09
EYN/A
EPS(NY)0.79
Fwd EY2.55%
FCF(TTM)-0.7
FCFYN/A
OCF(TTM)0.58
OCFY1.88%
SpS92.7
BVpS13.1
TBVpS13.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.89%
ROE -35.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 37.71%
FCFM N/A
ROA(3y)-0.27%
ROA(5y)3.43%
ROE(3y)-3.45%
ROE(5y)11.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.05%
GM growth 5Y-0.3%
F-Score4
Asset Turnover1.76
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 57.73%
Cap/Sales 1.38%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.12
Quick Ratio 0.39
Altman-Z 2.94
F-Score4
WACC9.59%
ROIC/WACCN/A
Cap/Depr(3y)80.1%
Cap/Depr(5y)94.79%
Cap/Sales(3y)2.05%
Cap/Sales(5y)2.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-330.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%153.13%
EPS Next Y73.05%
EPS Next 2Y47.36%
EPS Next 3Y35.42%
EPS Next 5Y24.22%
Revenue 1Y (TTM)1.85%
Revenue growth 3Y-8.76%
Revenue growth 5Y-0.75%
Sales Q2Q%8.29%
Revenue Next Year4.65%
Revenue Next 2Y4.63%
Revenue Next 3Y4.99%
Revenue Next 5Y6.03%
EBIT growth 1Y-85.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year118.7%
EBIT Next 3Y45.76%
EBIT Next 5Y30.74%
FCF growth 1Y-57.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.66%
OCF growth 3YN/A
OCF growth 5YN/A